Accueil   Diary - News   All news Focus on Erytech Pharma

Focus on Erytech Pharma

ERYTECH PHARMAErytech Pharma, bio- pharmaceutical company Lyonbiopole member, is specialized in encapsulation. The company has just completed a found raises of € 30 million on Euronext and announced at the same time the positive Phase III results from its pivotal study with GRASPA® in the treatment of acute Lyomphoblastic Leukemia. Rewarded on 21 October 2014 by EuropaBio 's Most Innovative European biotech SMEs trophy Erytech now heads to the United States with a new patent pending in the area of asparaginase

 

ABOUT ERYTECH PHARMA
 

Founded in 2004, ERYTECH Pharma develops innovative cancer therapies that work by starving tumours. Its first product, which is in phase III development, provides a therapeutic solution to frail patients with acute leukaemia.
 

ERYTECH proprietary technology is based on encapsulation of therapeutic molecules into red blood cells.
 

The company has a production unit located in Lyons with “Pharmaceutical Establishment” status. It has signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.

 

 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree